middle.news
Immutep Posts 30.9-Month Median Survival in 1L NSCLC INSIGHT-003 Trial
9:38am on Monday 13th of July, 2026 AEST
•
Biotechnology
Read Story
Immutep Posts 30.9-Month Median Survival in 1L NSCLC INSIGHT-003 Trial
9:38am on Monday 13th of July, 2026 AEST
Key Points
INSIGHT-003 reports median overall survival of 30.9 months in 1L non-squamous NSCLC
Majority of patients had low PD-L1 expression, a group with unmet needs
TACTI-004 Phase III trial stopped after failing to show superiority over placebo
Preliminary immune data reveal differing activation profiles between trials
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE